Text Size

Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2009 by Asan Medical Center.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Asan Medical Center
ClinicalTrials.gov Identifier:
NCT00885248
First received: April 20, 2009
Last updated: NA
Last verified: April 2009
History: No changes posted
  Purpose

In suspecting pancreatic cancer, dynamic phase pancreatic CT is the most effective tool in diagnosis and staging. In addition, magnetic resolution image, endoscopic ultrasonography, endoscopic retrograde pancreatography, angiography can be performed.

After introduction of functional image, PET has been suggested in the role of diagnosis and staging of pancreatic cancer. Furthermore, recently fused images of PET and CT were available.

In this study, the researchers evaluate the role of integrated PET-CT in patients with pancreatic cancer and analysis the cost-effectiveness of the integrated PET-CT.


Condition
Pancreatic Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Clinical Implication of Integrated PET-CT in the Patients With Pancreatic Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Asan Medical Center:

Primary Outcome Measures:
  • Staging of pancreatic cancer [ Time Frame: 6 months after study start ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Diagnosis of pancreatic cancer [ Time Frame: 6 months after study start ] [ Designated as safety issue: No ]

Estimated Enrollment: 70
Study Start Date: January 2009
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Detailed Description:

Compared to dynamic phase pancreatic CT, integrated PET-CT will be evaluated for sensitivity, specificity and accuracy of diagnosing and staging pancreatic cancer while the gold standard for pancratic cancer is operative specimen. If the operation can't be performed, EUS-FNA of the pancreatic mass or lymph node and additional imaging modality will be preferred to laparotomy.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The suspects of pancreatic cancer to visit Asan Medical Center in South Korea

Criteria

Inclusion Criteria:

  • Pancreatic mass suspicious of pancreatic cancer
  • No comorbidity, expected life expectancy less than 6 months
  • Consent this study in letter

Exclusion Criteria:

  • Refuse diagnostic and staging work-up
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00885248

Locations
Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of, 138-736
Sponsors and Collaborators
Asan Medical Center
  More Information

No publications provided

Responsible Party: Myung-Hwan Kim, Department of Internal Medicine, Asan Medical Center
ClinicalTrials.gov Identifier: NCT00885248     History of Changes
Other Study ID Numbers: 2008-0623
Study First Received: April 20, 2009
Last Updated: April 20, 2009
Health Authority: Korea: Food and Drug Administration

Keywords provided by Asan Medical Center:
pancreatic cancer
integrated PET-CT

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
 Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 16, 2013